Visual summary
Therapeutic approvals and trial results evolve. Verify the actual article, studied population, and current indication before teaching a treatment as established.
Text version
A protein-folding disease
Transthyretin deposition can produce a restrictive cardiomyopathy and extracardiac clues. Wild-type and hereditary disease require different family and genetic considerations.
Look beyond ejection fraction
Wall thickening, diastolic dysfunction, conduction disease, neuropathy, and carpal tunnel history can raise suspicion. Preserved ejection fraction does not imply a normal heart.
Exclude a monoclonal process
Monoclonal protein evaluation is essential when interpreting bone-tracer cardiac scintigraphy. A positive scan with monoclonal findings does not automatically establish ATTR.
Confirm the pathway
Use imaging, tissue when necessary, and genetic assessment after diagnosis. Resolve discordant tests rather than treating one characteristic pattern as definitive.
Individualize management
Coordinate specialist assessment for disease-specific therapy and cautious congestion management. Autonomic dysfunction and fixed stroke volume can limit tolerance of routine cardiac drugs.
Keep evidence current
Therapeutic approvals and trial results evolve. Verify the actual article, studied population, and current indication before teaching a treatment as established.
Continue learning
This graphic summarizes a topic. The full educational pages provide the broader discussion and references.